Jeffrey M. Leiden
2020 - Vertex Pharmaceuticals
In 2020, Jeffrey M. Leiden earned a total compensation of $16.5M as Executive Chairman at Vertex Pharmaceuticals, a 12% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $1,973,400 |
|---|---|
| Salary | $1,121,539 |
| Stock Awards | $13,335,168 |
| Other | $43,138 |
| Total | $16,473,245 |
Leiden received $13.3M in stock awards, accounting for 81% of the total pay in 2020.
Leiden also received $2M in non-equity incentive plan, $1.1M in salary and $43.1K in other compensation.
Rankings
In 2020, Jeffrey M. Leiden's compensation ranked 335th out of 13,090 executives tracked by ExecPay. In other words, Leiden earned more than 97.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 335 out of 13,090 | 97th |
Division Manufacturing | 114 out of 5,621 | 98th |
Major group Chemicals And Allied Products | 39 out of 2,254 | 98th |
Industry group Drugs | 35 out of 1,954 | 98th |
Industry Pharmaceutical Preparations | 23 out of 1,459 | 98th |
Source: SEC filing on April 7, 2022.
Leiden's colleagues
We found three more compensation records of executives who worked with Jeffrey M. Leiden at Vertex Pharmaceuticals in 2020.